Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31122901

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2019 Jul
First author
West H

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Jul;20(7):889-891. doi: 10.1016/S1470-2045(19)30148-2.
    note
    Source null
    related pmid
    31122902
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2019 Sep;20(9):e466. doi: 10.1016/S1470-2045(19)30498-X.
    note
    Source null
    related pmid
    31486365
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2019 Sep;20(9):e467. doi: 10.1016/S1470-2045(19)30544-3.
    note
    Source null
    related pmid
    31486366
    relationship
    Comment in
  4. citation
    Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S447-S450. doi: 10.21037/tlcr.2019.11.10.
    note
    Source null
    related pmid
    32038935
    relationship
    Comment in
  5. citation
    Transl Cancer Res. 2019 Dec;8(8):E11-E14. doi: 10.21037/tcr.2019.12.57.
    note
    Source null
    related pmid
    35117056
    relationship
    Comment in
  6. citation
    Transl Cancer Res. 2019 Dec;8(8):E18-E23. doi: 10.21037/tcr.2019.12.69.
    note
    Source null
    related pmid
    35117058
    relationship
    Comment in
  7. citation
    Transl Cancer Res. 2020 Mar;9(3):1311-1318. doi: 10.21037/tcr.2020.01.20.
    note
    Source null
    related pmid
    35117478
    relationship
    Comment in

Authors and identifiers

  1. name
    West H
    type
    Author
  2. name
    McCleod M
    type
    Author
  3. name
    Hussein M
    type
    Author
  4. name
    Morabito A
    type
    Author
  5. name
    Rittmeyer A
    type
    Author
  6. name
    Conter HJ
    type
    Author
  7. name
    Kopp HG
    type
    Author
  8. name
    Daniel D
    type
    Author
  9. name
    McCune S
    type
    Author
  10. name
    Mekhail T
    type
    Author
  11. name
    Zer A
    type
    Author
  12. name
    Reinmuth N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    West H
    type
    Author
  2. name
    McCleod M
    type
    Author
  3. name
    Hussein M
    type
    Author
  4. name
    Morabito A
    type
    Author
  5. name
    Rittmeyer A
    type
    Author
  6. name
    Conter HJ
    type
    Author
  7. name
    Kopp HG
    type
    Author
  8. name
    Daniel D
    type
    Author
  9. name
    McCune S
    type
    Author
  10. name
    Mekhail T
    type
    Author
  11. name
    Zer A
    type
    Author
  12. name
    Reinmuth N
    type
    Author
bibliography ids
  1. nci-bib-86151163e223b2c6ab42463e
book metadata
content sha256
a5d7ebb8ac1728c9cd43205aa16f8a2708f9ac7f970b5840767c15f5c445b4a3
document type
citation
dois
  1. 10.1016/S1470-2045(19)30167-6
electronic publication date
display
2019 May 20
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31122901
immutable id
pubmed:31122901@a5d7ebb8ac1728c9cd43205aa16f8a2708f9ac7f970b5840767c15f5c445b4a3
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
924-937
volume
20
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Jul;20(7):889-891. doi: 10.1016/S1470-2045(19)30148-2.
    note
    Source null
    related pmid
    31122902
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2019 Sep;20(9):e466. doi: 10.1016/S1470-2045(19)30498-X.
    note
    Source null
    related pmid
    31486365
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2019 Sep;20(9):e467. doi: 10.1016/S1470-2045(19)30544-3.
    note
    Source null
    related pmid
    31486366
    relationship
    Comment in
  4. citation
    Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S447-S450. doi: 10.21037/tlcr.2019.11.10.
    note
    Source null
    related pmid
    32038935
    relationship
    Comment in
  5. citation
    Transl Cancer Res. 2019 Dec;8(8):E11-E14. doi: 10.21037/tcr.2019.12.57.
    note
    Source null
    related pmid
    35117056
    relationship
    Comment in
  6. citation
    Transl Cancer Res. 2019 Dec;8(8):E18-E23. doi: 10.21037/tcr.2019.12.69.
    note
    Source null
    related pmid
    35117058
    relationship
    Comment in
  7. citation
    Transl Cancer Res. 2020 Mar;9(3):1311-1318. doi: 10.21037/tcr.2020.01.20.
    note
    Source null
    related pmid
    35117478
    relationship
    Comment in
outcomes validated
false
pmid
31122901
provenance
batch id
23ffe1e2a9e160b6dca0
provider
NCBI PubMed ESummary
record sha256
2b4db1ea54fb3fa2ac46426ab728f6c0774c405f8cec63eb48f27e6a3b114661
response sha256
d5cbfde8f87ba85b214c53aaf0e8fa33d70fec48dd4fde7745538180cd7e1841
retrieved at
2026-09-09T23:47:44.690737+00:00
publication date
display
2019 Jul
precision
month
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31122901/
title
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice